Serratiopeptidase: Uses, Side Effects, Precautions and Dosage

Medically Reviewed By Dr. Neelam Bisht, M.D. Medicine ( S.N.Medical College Agra, 1998),M.B.B.S ( K.G.Medical College Lucknow, 1993), Principal Consultant - Internal Medicine

Serratiopeptidase

Serratiopeptidase is a proteolytic enzyme derived from the nonpathogenic bacterium Serratia marcescens (originally isolated from the intestine of the silkworm Bombyx mori). It hydrolyses proteins involved in oedema, fibrin deposition and inflammatory exudates making it useful as an anti-inflammatory, anti-oedematous and fibrinolytic agent. Serratiopeptidase is widely prescribed as an adjunct in postsurgical recovery, musculoskeletal conditions and sinusitis. It is available as enteric-coated tablets to protect the enzyme from gastric acid degradation.

What is Serratiopeptidase Used For

Doctors prescribe serratiopeptidase for:

• Postoperative and post-traumatic swelling: Adjunctive reduction of oedema following dental extractions, orthopaedic procedures and soft tissue injuries

• Sinusitis and upper respiratory inflammation: Reduces mucosal oedema and viscosity of nasal and bronchial secretions

• Musculoskeletal pain: Carpal tunnel syndrome, tendinitis and periarthritis where fibrin-mediated swelling contributes to symptoms.

• Chronic venous insufficiency: Adjunct to reduce lower limb oedema and heaviness.

• Breast engorgement: Used in non-lactational mastitis and postoperative breast swelling.

• Atherosclerotic plaque: Experimental evidence for fibrinolytic action on arterial fibrin deposits.

How Does Serratiopeptidase Work

Serratiopeptidase exerts its primary effects through serine protease activity, hydrolysing bradykinin, fibrin and other pro-inflammatory proteins at sites of tissue injury. Bradykinin is a key mediator of vascular permeability and pain sensitisation and its breakdown reduces capillary leakage and attenuates the oedema cascade. Fibrinolytic activity degrades cross-linked fibrin deposits that form in inflamed tissues, improving localised microcirculation and reducing induration at surgical or injury sites.

Additionally, serratiopeptidase degrades the protein coat of inflammatory exudates thus thinning viscous secretions in the respiratory tract and sinuses. This mucolytic property supports mucus clearance without triggering bronchoconstriction. Enteric coating is essential as gastric acid irreversibly denatures the enzyme, so intact intestinal absorption is the prerequisite for any systemic activity.

Serratiopeptidase for Swelling and Inflammation

Dental surgery research shows that serratiopeptidase 10 mg three times daily reduces post-extraction facial swelling, trismus and pain at 3 and 7 days. A meta-analysis of five dental trials found a statistically significant reduction in cheek circumference at 72 hours. In sinusitis, serratiopeptidase reduces mucosal thickness measurable on diagnostic imaging and improves symptom scores for nasal congestion and facial pressure within 7 to 14 days of treatment.

Serratiopeptidase After Surgery or Injury

Following orthopaedic and general surgical procedures, postoperative oedema prolongs recovery, restricts joint mobilisation and increases analgesic requirement. Serratiopeptidase prescribed at 5 to 10 mg twice or three times daily in the immediate postoperative period has reduced wound oedema and pain.

In acute soft tissue injuries like ankle sprains, haematomas and ligament strains starting within 48 hours of injury reduces swelling and accelerates return to functional mobility. It is commonly co-prescribed with NSAIDs in the acute phase and continued alone once inflammation control transitions to recovery support.

Serratiopeptidase Dosage and How to Take It

• Standard adult dose: 5 to 10 mg (50,000 to 100,000 IU) two to three times daily taken on an empty stomach at least 30 minutes before a meal

• Postsurgical or acute inflammatory use: 10 mg three times daily for 7 to 14 days, then reduced based on clinical response.

• Chronic conditions (sinusitis, musculoskeletal): 5 mg twice daily for 4 to 8 weeks; duration determined by the doctor.

Tablets must be swallowed whole as chewing or crushing destroys the enteric coating and renders the enzyme inactive before intestinal absorption.

Do not take with antacids, H2 blockers or proton pump inhibitors immediately before dosing as these raise gastric pH but do not substitute for enteric coating protection during gastric transit.

Serratiopeptidase Side Effects

Common side effects are:

• Gastrointestinal disturbances: Nausea, epigastric discomfort and loose stools (typically mild and resolving with continued use or dose reduction)

• Skin reactions: Pruritus, urticaria and maculopapular rash 

• Bleeding tendency: Serratiopeptidase inhibits platelet aggregation and exerts fibrinolytic activity; combined use with anticoagulants or antiplatelet agents increases bleeding risk

• Pneumonitis: Rare case of hypersensitivity pneumonitis with chronic serratiopeptidase use

• Elevated liver enzymes: Isolated cases of transient aminotransferase elevation have been documented so hepatic monitoring is warranted with prolonged use.

Who Should Avoid Serratiopeptidase

Certain groups of people should avoid serratiopeptidase. They are:

• Bleeding Disorders or Anticoagulant Therapy: Patients on warfarin, heparin, rivaroxaban or antiplatelet agents such as aspirin and clopidogrel face should avoid serratiopeptidase as it increases haemorrhagic risk. 

• Pre-operative Patients: Serratiopeptidase should be discontinued at least 7 days before elective surgery due to its antiplatelet and fibrinolytic properties, which may increase intraoperative and postoperative bleeding.

• Hepatic or Renal Impairment: Enzyme metabolism and elimination pathways are incompletely characterised in hepatic or renal failure. Safety data in these populations are insufficient to recommend routine use without specialist guidance.

• Children and Adolescents: Serratiopeptidase should not be used in children without explicit prescriber supervision.

Precautions

• Inform the prescriber of all concurrent medications particularly anticoagulants, NSAIDs and antiplatelet drugs before starting serratiopeptidase.

• Avoid use in the 7 days immediately preceding any planned surgical or dental procedure.

• Pregnant and breastfeeding women use only when clinically indicated and under medical supervision.

• Do not self-prescribe serratiopeptidase for symptoms suggesting deep vein thrombosis, pulmonary embolism or severe infection.

• Monitor for new respiratory symptoms, skin eruptions or unexplained bruising during treatment and report promptly to the doctor.

Drug Interactions with Serratiopeptidase

Key drug interactions are:

• Antibiotics like amoxicillin and ofloxacin

• Anticoagulants like warfarin, rivaroxaban, apixaban

• Antihypertensives

• Antiplatelet agents like aspirin, clopidogrel, ticagrelor

• Corticosteroids

• NSAIDs 

• Digoxin

• Lithium

• Methotrexate.

Conclusion

Serratiopeptidase is a clinically useful proteolytic enzyme for managing postoperative oedema, musculoskeletal inflammation and sinus congestion. Its mechanism (fibrinolysis, bradykinin degradation and mucolysis) addresses multiple inflammatory pathways simultaneously. Correct formulation adherence, appropriate patient selection excluding those on anticoagulants or facing surgery and physician-supervised dosing duration are essential for safe, effective use.

FAQs

1. What is Serratiopeptidase used for?

   Serratiopeptidase is prescribed to reduce postoperative and post-traumatic swelling, manage sinusitis and nasal congestion, relieve musculoskeletal inflammation in conditions such as carpal tunnel syndrome & tendinitis and support recovery following dental extractions and orthopaedic procedures.

2. Does Serratiopeptidase help reduce swelling and inflammation?

   Yes by hydrolysing bradykinin and fibrin at injury sites, serratiopeptidase reduces vascular permeability, limits oedema formation and degrades fibrin deposits that sustain swelling. Controlled dental surgery trials confirm measurable reductions in facial oedema at 72 hours compared to placebo.

3. What are the side effects of Serratiopeptidase tablet?

   Common side effects are nausea, epigastric discomfort and loose stools. Less common effects are skin rash and urticaria. Rare serious effects include hypersensitivity pneumonitis and increased bleeding tendency particularly when combined with anticoagulants or antiplatelet medications.

4. How should Serratiopeptidase tablet be taken?

   Swallow enteric-coated tablets whole with water on an empty stomach, at least 30 minutes before eating. Do not crush, chew or split tablets as this destroys the coating and denatures the enzyme before intestinal absorption.

5. Can Serratiopeptidase be taken with painkillers?

   Co-prescription with NSAIDs such as ibuprofen or diclofenac is common in acute inflammation. However combined use increases gastrointestinal mucosal risk. Combining serratiopeptidase with anticoagulants or antiplatelet agents requires physician supervision due to additive bleeding risk.

6. Is Serratiopeptidase safe for long-term use?

   Long-term safety data are limited. Short-term courses of 7 to 14 days are well-documented. Prolonged use beyond 8 weeks warrants liver enzyme monitoring and clinical review. Patients should not self-prescribe extended courses without periodic reassessment by the doctor.

7. How long does Serratiopeptidase take to work?

   Postsurgical oedema typically begins to reduce within 48 to 72 hours of starting serratiopeptidase. Sinusitis symptom improvement is usually measurable within 7 to 14 days. Musculoskeletal conditions may require 3 to 4 weeks of consistent use before significant symptomatic relief is observed.

8. Is Serratiopeptidase safe during pregnancy?

   Human safety data in pregnancy are insufficient. Serratiopeptidase should be used during pregnancy only when clinically necessary and under direct medical supervision with risks and benefits explicitly discussed.

9. Can Serratiopeptidase be taken on an empty stomach?

   Yes an empty stomach is specifically required. Food raises intragastric pH and accelerates gastric emptying variably, but more importantly, food slows intestinal transit, extending enzyme contact time with the intestinal wall. Enteric coating releases the enzyme in the alkaline intestinal environment, not the stomach.

10. What precautions should be taken before using Serratiopeptidase?

    Disclose all anticoagulant, antiplatelet or NSAID use to the doctor. Discontinue at least 7 days before any planned surgery or dental procedure. Do not use in active bleeding disorders. Seek medical assessment before use in liver disease or kidney impairment.

References

1. Mazzone A, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomised trial versus placebo. J Int Med Res. 1990;18(5):379-388.

2. Bhagat S, et al. Comparison of serratiopeptidase and diclofenac sodium in the management of pain and swelling after dental extractions. J Oral Sci. 2013;55(3):195-199.

3. Moriya N, et al. Enhancement of drug-induced inhibition of bacterial lung infection in mice by combination treatment with serratiopeptidase. Biol Pharm Bull. 1994;17(1):56-61.

4. Panagariya A, Sharma AK. A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome. J Assoc Physicians India. 1999;47(12):1170-1172.

5. Esch PM, et al. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase — a prospective study. Fortschr Med. 1989;107(4):67-68.

6. Kee WH, et al. The treatment of breast engorgement with serrapeptase (Danzen): a randomised double-blind controlled trial. Singapore Med J. 1989;30(1):48-54.

7. Tago T, Sato M. Non-enteric coated tablets of serrapeptase: clinical evaluation of their utility in the treatment of chronic inflammation and swelling. Jpn J New Drugs. 1984;21:243-250.

8. Shinde BG, et al. Efficacy of serratiopeptidase 10 mg as compared to aceclofenac 100 mg in reduction of postoperative dental swelling, pain, and trismus: a randomised controlled trial. J Dent Res Rev. 2017;4(3):60-65.

Dr. Neelam Bisht

Principal Consultant - Internal Medicine

Meet the Doctor